Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic investigation of smoking cessation treatment.

Pharmacogenetics - 1 Nov 2002

Lerman Caryn, Shields Peter G, Wileyto E Paul, Audrain Janet, Pinto Angela, Hawk Larry, Krishnan Shiva, Niaura Ray, Epstein Leonard

Abstract excerpt

Despite the efficacy of bupropion for smoking cessation, smokers exhibit variability in treatment outcome. The CYP2B6 gene has been implicated in bupropion kinetics and nicotine metabolism, and is a plausible candidate for pharmacogenetic studies of treatment response. We investigated whether a f...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Bupropion
Share to Cytochrome P-450 CYP2B6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ethnicity

Share to Oxidoreductases, N-Demethylating

Share to Pharmacogenetics

Share to Placebos

Share to Smoking Cessation

Source

Identifiers

PMID: 12439223
DOI: 10.1097/00008571-200211000-00007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-12439223-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic investigation of smoking cessation treatment.PMID 12439223Read ↗

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationSemantic proximity Read ↗

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.Semantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Semantic proximity Read ↗

The Role of Pharmacogenetics in Smoking.Semantic proximity Read ↗

Pharmacogenetics and nicotine addiction treatment.Semantic proximity Read ↗

CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes.Semantic proximity Read ↗

Smoking cessation treatment: pharmacogenetic assessment.Semantic proximity Read ↗

Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review.Semantic proximity Read ↗

Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.Semantic proximity Read ↗

Pharmacogenetics of smoking cessation therapySemantic proximity Read ↗

Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.